CJC-1295 No DAC / Ipamorelin Blend (5mg / 5mg)

The CJC-1295 No DAC / Ipamorelin blend targets the GH axis through two complementary and mutually reinforcing molecular pathways, producing synergistic GH release that replicates the dual-signal architecture of endogenous pituitary regulation.

CJC-1295 No DAC — GHRH Receptor Pathway

CJC-1295 No DAC binds to and activates the GHRH receptor (GHRHR) — the same Gαs-coupled GPCR targeted by endogenous hypothalamic GHRH and by tesamorelin — on somatotroph cells of the anterior pituitary:

• GHRHR activation stimulates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP)
• Elevated cAMP activates Protein Kinase A (PKA), which phosphorylates the transcription factor CREB — driving expression of the GH1 gene (somatotropin)
• PKA signaling also triggers opening of voltage-gated calcium channels, raising intracellular Ca²⁺ and driving exocytosis of GH secretory granules from somatotroph cells
• The result is a sharp, pulsatile GH release event triggered within minutes of administration that dissipates as CJC-1295 No DAC is rapidly cleared (half-life ~30 min)

Preclinical data with CJC-1295 (both DAC and No DAC variants) demonstrates additional effects at the cellular level: increased GH mRNA expression and evidence of somatotroph cell proliferation with repeated exposure — suggesting that sustained use may upregulate the pituitary’s GH production capacity rather than merely triggering release of existing stores.​

Ipamorelin — GHS-R1a / Ghrelin Receptor Pathway

Ipamorelin targets a completely distinct receptor from CJC-1295 No DAC — the Growth Hormone Secretagogue Receptor 1a (GHS-R1a), also known as the ghrelin receptor:

• GHS-R1a is a Gαq/11-coupled GPCR whose endogenous ligand is ghrelin, a 28-amino acid peptide primarily produced by gastric oxyntic cells in response to fasting
• Ipamorelin binding to GHS-R1a activates phospholipase C (PLC), generating IP₃ and DAG — triggering intracellular calcium release from the endoplasmic reticulum and PKC activation
• This IP₃/Ca²⁺ pathway leads to GH granule exocytosis through a mechanism entirely independent of cAMP/PKA signaling
• Ipamorelin also activates GHS-R1a receptors in the hypothalamus, suppressing somatostatin (GH’s inhibitory signal) and potentially increasing endogenous GHRH tone — creating a permissive environment for greater GH secretion​

Receptor Selectivity — Ipamorelin’s Critical Pharmacological Distinction

The 1998 Raun et al. characterization established ipamorelin as the first GH secretagogue to demonstrate GHRH-like selectivity:​

• Unlike GHRP-2 and GHRP-6, which robustly stimulate ACTH, cortisol, and prolactin through GHS-R1a off-target signaling, ipamorelin produces negligible ACTH, cortisol, and prolactin elevation at GH-effective doses
• This selectivity reflects biased agonism at GHS-R1a — ipamorelin stabilizes receptor conformations that preferentially activate GH-related G protein signaling over other downstream effectors linked to cortisol and appetite stimulation
• The result: a clean, isolated GH pulse without the hypercortisolemia, hyperprolactinemia, or intense hunger that limited clinical enthusiasm for earlier GHRPs​

The Synergistic Mechanism — Why the Combination Exceeds the Sum of Its Parts

The scientific basis for this combination traces to decades of research establishing that GHRH and GHS/ghrelin co-stimulation is synergistic at the somatotroph level:

• The two pathways converge on somatotroph Ca²⁺ mobilization from different upstream inputs (cAMP/PKA → calcium channels via CJC-1295 No DAC; IP₃ → ER calcium release via ipamorelin) — together creating a larger intracellular Ca²⁺ transient than either pathway alone
• CJC-1295 No DAC primes the somatotroph by loading it with cAMP-driven GH transcription and sensitizing the secretory machinery; ipamorelin then triggers the exocytotic event with maximal efficiency against a pre-primed cellular backdrop
• The combination also counteracts somatostatin inhibition more effectively: GHRH reduces somatostatin sensitivity, while GHS-R1a agonism actively suppresses somatostatin release — together dismantling the main brake on GH secretion simultaneously​
• The combined GH pulse is more sustained than ipamorelin alone (due to CJC-1295 No DAC’s GHRH receptor occupancy persisting beyond the initial ipamorelin-triggered release)

Pulsatility — The Key Advantage of the No DAC Formulation

The choice of CJC-1295 without DAC for this blend is pharmacologically deliberate:

• CJC-1295 with DAC’s 6–8 day half-life produces continuous, non-pulsatile GHRH receptor stimulation — a pattern associated with pituitary desensitization (downregulation of GHRHR), prolonged IGF-1 elevation, and less physiological GH dynamics
• CJC-1295 No DAC’s ~30-minute half-life delivers brief GHRH receptor activation that clears rapidly, allowing the pituitary to reset between doses and preserving the pulsatile GH secretion pattern that is essential for physiological downstream effects — including GH receptor sensitivity in peripheral tissues and normal hepatic IGF-1 dynamics
• Combining short-acting CJC-1295 No DAC with ipamorelin (~2h half-life) produces GH pulses with a physiological rise-and-fall profile separated by appropriate troughs, reducing the risk of receptor desensitization

GH Downstream Effects

Once released, the GH pulse generated by the combination produces the same downstream effects as endogenous GH through GH receptor (GHR) signaling:​

• Liver IGF-1 production: GH activates hepatic GHR → JAK2/STAT5 → IGF-1 gene transcription; IGF-1 then mediates most of GH’s anabolic effects via IGF-1R signaling (protein synthesis, satellite cell activation, anti-apoptosis)
• Direct lipolysis: GH activates HSL/ATGL in adipocytes independent of IGF-1; pulsatile GH particularly enhances visceral fat lipolysis
• Anti-insulin effect: Acute GH pulses transiently reduce insulin sensitivity in muscle and fat; this reverses during the inter-pulse trough, preserving overall glucose homeostasis when pulsatility is maintained
• Protein synthesis: Increased amino acid transport and mTOR pathway activation through IGF-1/IGF-1R in muscle

Connective tissue: GH and IGF-1 promote collagen synthesis in tendons, ligaments, and cartilage through TGF-β and direct IGF-1R signaling

The research evidence base for this combination requires careful parsing into three tiers: robust human data for CJC-1295 (with DAC, the pharmacologically similar but longer-acting version), preclinical and Phase 2 data for ipamorelin, and limited but mechanistically compelling evidence for the combination specifically.

CJC-1295 Human Pharmacokinetic / Pharmacodynamic Data

The foundational human evidence for CJC-1295 comes from a randomized, double-blind, placebo-controlled dose-escalation trial published in The Journal of Clinical Endocrinology & Metabolism (2006) — the most rigorously conducted human study of any GHRH analog outside of tesamorelin:​

• Design: Healthy adults (21–61 years), single or multiple subcutaneous injections of CJC-1295 (with DAC) at doses from 30–120 μg/kg
• GH response: Single doses produced 2–10 fold increases in GH above baseline over 6+ days; dose-dependent and sustained
• IGF-1 response: Mean IGF-1 levels increased 1.5–3 fold above baseline, remaining elevated for 9–11 days following a single injection
• Multiple doses maintained elevated GH and IGF-1 for up to 28 days with no serious adverse reactions
• Safety: Well tolerated; most common adverse events were injection site reactions and transient facial flushing/vasodilation; no significant changes in glucose, cortisol, or prolactin

This study provides the strongest available human pharmacological evidence for the class, though it used the DAC version — the No DAC variant (shorter half-life, pulsatile kinetics) is expected to produce qualitatively similar but temporally compressed GH stimulation.​

Ipamorelin Human Data

• Original pharmacological characterization (Raun et al., 1998): Ipamorelin stimulated GH in anesthetized rats with potency and efficacy comparable to GHRP-6 (ED₅₀ ~80 nmol/kg, Emax ~1545 ng/mL GH) while producing no significant cortisol or ACTH elevation at any dose tested — establishing its extraordinary selectivity​
• Phase 2 Clinical Trial — Postoperative Ileus (2014): A randomized, double-blind, placebo-controlled Phase 2 trial evaluated ipamorelin (via IV infusion for up to 7 days) in patients with postoperative ileus. Ipamorelin was well tolerated with no significant safety signals, though it did not demonstrate superiority over placebo for the GI endpoint. This remains the most rigorous human safety dataset for ipamorelin​
• Pharmacokinetic modeling (1999): Population PK/PD modeling in healthy adults confirmed ipamorelin’s ~2-hour terminal half-life and characterized its GH pulse as finite, time-limited, and dose-dependent without hormonal spillover​
• Bone research: Ipamorelin increased bone mineral content and bone density in preclinical models through GH/IGF-1 axis stimulation, suggesting utility in osteoporosis models​

GHRH + GHS Synergy — Foundational Evidence

The synergistic interaction between GHRH-pathway agents and GHS-pathway agents is one of the most reproducible findings in GH axis pharmacology:​

• A landmark study (PMID 10372741) demonstrated that simultaneous stimulation of both GHRHR and GHS-R1a produces a GH response significantly greater than the arithmetic sum of responses to each agent alone in both in vitro pituitary cell preparations and in vivo animal models
• This synergy was reproducible across multiple GHRH analogs (including Mod GRF 1-29) and multiple GHS peptides (including ipamorelin), confirming it is a class effect rooted in convergent intracellular signaling rather than a compound-specific property​

Body Composition — What the Research Actually Shows

An important caveat must accompany the extensive community discourse around this combination:​

• The GH and IGF-1 elevations produced by CJC-1295 in human trials are well-documented and significant
• However, hard outcome data (lean mass gain, fat loss, strength improvement) in healthy individuals using this combination has not been rigorously established in published controlled trials
• The available positive body composition and recovery outcomes are inferred from the known downstream effects of GH/IGF-1 elevation generally, and from anecdotal clinical experience at specialty longevity and wellness clinics — not from double-blind trials measuring these endpoints
• GH deficiency populations (GHD, age-related GH decline, HIV lipodystrophy) show clear body composition benefits from GH-axis stimulation; extrapolation to healthy, younger individuals with normal GH secretion is less well supported

Gastrointestinal Motility Research

Ipamorelin’s GHS-R1a activity extends to enteric neurons expressing the ghrelin receptor, making it the subject of preclinical and Phase 2 research for postoperative ileus and gastroparesis, reflecting GH-independent gastrointestinal effects that are an active area of investigation.​

Regulatory Status — FDA

Both CJC-1295 No DAC and Ipamorelin occupy an evolving and actively contested regulatory position in the United States:

• Neither compound is FDA-approved for any human therapeutic indication
• Section 503A Category 2 (Compounding): Both CJC-1295 and Ipamorelin appear on the FDA’s Section 503A Category 2 bulk drug substance list, which signals that the FDA has identified significant safety, effectiveness, or purity concerns for compounding. Placement on Category 2 effectively prohibits compounding pharmacies from preparing these substances for patient use under the 503A pathway
• Legal Challenge and Partial Settlement (2024): In late 2023, Evexias Medical Group and Farmakeio compounding pharmacy sued the FDA, alleging that the categorical movement of these peptides to Category 2 violated proper notice-and-comment rulemaking procedures. In September 2024, a settlement required the FDA to submit CJC-1295 and Ipamorelin for formal public review by the Pharmacy Compounding Advisory Committee (PCAC) rather than maintaining the unilateral ban. As of early 2026, this PCAC review process is ongoing — meaning the regulatory status remains in active flux​
• FDA’s stated concerns for CJC-1295: Potential cardiovascular adverse events (flagged from adverse event reports), immunogenicity risks, and insufficient clinical safety data
• Research use only: Both compounds remain legally available as research chemicals labeled “not for human use”

WADA Status — Explicitly Prohibited by Name

Both compounds are explicitly named on the WADA 2025 and 2026 Prohibited Lists under Section S2.2.4 — Growth Hormone Releasing Factors and Their Mimetics:

• CJC-1295: Listed by name under GHRH analogs: “growth hormone-releasing hormone (GHRH) and its analogues (e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin)”
• Ipamorelin: Listed by name under GHS mimetics: “growth hormone secretagogues (GHS) and their mimetics [e.g. anamorelin, capromorelin, ibutamoren (MK-677), ipamorelin, lenomorelin (ghrelin), macimorelin and tabimorelin]”
• Banned at all times, both in- and out-of-competition

DoD: CJC-1295 is also relevant to U.S. military drug testing under the DoD’s adoption of the WADA framework

CJC-1295 — Human Safety Data (from 2006 Phase 1/2 Trial)

The available human safety data for CJC-1295 comes primarily from the 2006 dose-escalation trial:

• Well tolerated across all dose groups (30–120 μg/kg SC)
• Most common adverse events: Injection site reactions (erythema, swelling), transient facial flushing and vasodilation after injection (related to acute GH-induced vasodilation/nitric oxide effects), and mild headache
• No significant changes in fasting glucose, insulin, cortisol, prolactin, TSH, LH, FSH, or other pituitary hormones at any dose
• No serious adverse events reported in the trial
• The FDA flagged cardiovascular adverse event reports from post-market sources (outside the controlled trial context) as part of its 503A Category 2 decision, though the nature, frequency, and causality of these reports have not been publicly characterized in detail​

Ipamorelin — Human Safety Data

• Phase 2 postoperative ileus trial: Ipamorelin was well tolerated up to 7 days of continuous IV infusion with no clinically significant safety signals​
• No cortisol elevation: Ipamorelin does not raise cortisol at GH-effective doses — a significant safety advantage over GHRP-2 and GHRP-6, which can cause clinically relevant hypercortisolism
• No prolactin elevation: Unlike other GH secretagogues, ipamorelin does not stimulate prolactin — relevant for both male and female users​
• No appetite stimulation at standard doses: The hunger/appetite stimulation associated with ghrelin receptor agonism is markedly attenuated with ipamorelin compared to GHRP-6, consistent with its biased agonism at GHS-R1a​

Common Adverse Effects of the Combination

Based on preclinical data, the 2006 CJC-1295 human trial, and clinical experience with GH-axis stimulating agents generally:

• Injection site reactions: Redness, swelling, and discomfort at the subcutaneous injection site — the most consistently reported adverse effect
• Transient flushing / head rush: Acute vasodilation following injection, lasting minutes; particularly with CJC-1295​
• Water retention / edema: GH-mediated anti-natriuretic effects cause soft tissue fluid retention, particularly in initial weeks of use; can manifest as puffiness of hands, face, and feet
• Transient hypoglycemia: Acute GH pulse transiently suppresses insulin signaling; some users report mild lightheadedness or hunger shortly after administration — generally managed by ensuring food intake within 1–2 hours of dosing
• Paresthesias: Tingling in extremities related to fluid retention and potential mild carpal tunnel effects from soft tissue swelling; similar to what is observed with GH administration

Theoretical Safety Concerns

• Cancer promotion: The same IGF-1 elevation risk that applies to tesamorelin applies here — sustained IGF-1 elevation above physiological norms is associated with increased cancer risk in epidemiological data (see IGF-1 LR3 and tesamorelin pages for detail). The feedback-mediated ceiling on IGF-1 elevation that characterizes GHRH analog use is a meaningful safety mitigant, but this risk is not eliminated​
• Pituitary desensitization: With the No DAC formulation and appropriate dosing intervals, pituitary desensitization risk is substantially lower than with CJC-1295 DAC; however, chronic daily use without appropriate cycling could theoretically reduce pituitary responsiveness over time
• Glucose metabolism: The anti-insulin properties of GH pulses are transient with pulsatile dosing but can accumulate with very frequent dosing — individuals with pre-existing insulin resistance or pre-diabetes require glucose monitoring
• Manufacturing quality: Both peptides are available through unregulated commercial suppliers; purity, contamination, and peptide integrity are significant real-world concerns in the absence of GMP manufacturing oversight

Important Distinction from Exogenous GH

A key safety consideration is the preserved feedback architecture of this combination:

• Like tesamorelin, CJC-1295 No DAC and Ipamorelin work upstream — stimulating the pituitary to release the body’s own GH in physiological pulses
• Rising IGF-1 feeds back to suppress GHRH secretion and increase somatostatin tone — providing a natural ceiling on GH and IGF-1 that exogenous GH bypasses entirely
• This makes the acromegaly-like overshoot observed with exogenous GH (joint hypertrophy, organomegaly, carpal tunnel, diabetogenic effects) substantially less likely at appropriate doses
• However: this feedback ceiling is not absolute, and individual responsiveness varies; some subjects show IGF-1 elevations above age-adjusted normal ranges even with this combination

1. Raun, K., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. 
2. Teichman, S.L., et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. 
3. Sackmann-Sala, L., et al. (2009). Activation of the GH/IGF-1 axis by CJC-1295 results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research, 19(6), 471–477. 
4. Particle Peptides. Modified GRF 1-29 (CJC-1295 No DAC) — Structural Overview and Amino Acid Substitutions. 
5. Revolution Health & Wellness. (2025). CJC-1295 With DAC vs Without DAC. 
6. BioTech Peptides. (2025). Pharmacological and Metabolic Insights into the Ipamorelin / CJC-1295 Blend. 
7. Spartan Peptides. (2026). CJC-1295 and Ipamorelin: The Research-Backed GH Secretagogue Stack. 
8. BodySpec. (2026). CJC-1295 Ipamorelin: Research, Safety, and Results. 
9. Care America Pharmacy. Growth Hormone / Ipamorelin Clinical Overview. 
10. BSCG. (2026). CJC-1295 Use in Sports and Military Rules Explained. 
11. World Anti-Doping Agency. 2026 Prohibited List International Standard, Section S2.2.4. 
12. Safe Harbor Group. (2026). FDA’s Overreach on Compounded Peptides: Legal Battles and How Clinics Can Push Back. 
13. Veedma Health. (2025). Are Peptides Legal in the US? FDA Rules for 2026. 
14. Beverly Hills Rejuvenation Center. (2026). Potential FDA Peptide Reclassification 2026. 
15. Elite NP. (2026). FDA Peptide Reclassification 2026: What It Means for Providers and Patients. 
16. Advanced TRT Clinic. (2024). Ipamorelin & CJC-1295 Banned — Now What? 
17. Ipamorelin: A Selective Ghrelin-Mimetic Peptide in Contemporary Signaling Research. (2026). Social Life Magazine.